Coronavirus Update: Moderna Progesses To Phase II, Russia Approves Homegrown Antiviral
CanSino Has Produced Fuller Data
Executive Summary
Moderna maintains its lightning pace, but questions about its Phase III trial design remain.
You may also be interested in...
BIO Calls For Journal Publication Of COVID-19 Trial Data, Independent FDA
In an open letter to the biopharmaceutical industry, BIO lays out principles for conducting COVID-19 clinical trials and disclosing and using the data. Senator Durbin asks eight vaccine makers backed by Operation Warp Speed how they will withstand political pressure to speed up the approval process.
Celltrion Progresses COVID-19 Antibody Therapeutic, Pricing Will Be Key
Celltrion presses ahead with Phase I study of COVID-19 antibody therapeutic, encouraged by the support of the South Korean government. The firm also urges global cooperation to lower prices of COVID-19 drugs and vaccines to end the global pandemic.
Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses
Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.